| pubmed-article:17083268 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17083268 | lifeskim:mentions | umls-concept:C0005847 | lld:lifeskim |
| pubmed-article:17083268 | lifeskim:mentions | umls-concept:C0003009 | lld:lifeskim |
| pubmed-article:17083268 | lifeskim:mentions | umls-concept:C1521970 | lld:lifeskim |
| pubmed-article:17083268 | lifeskim:mentions | umls-concept:C0386393 | lld:lifeskim |
| pubmed-article:17083268 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:17083268 | lifeskim:mentions | umls-concept:C1442488 | lld:lifeskim |
| pubmed-article:17083268 | lifeskim:mentions | umls-concept:C0683598 | lld:lifeskim |
| pubmed-article:17083268 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:17083268 | lifeskim:mentions | umls-concept:C0332206 | lld:lifeskim |
| pubmed-article:17083268 | lifeskim:mentions | umls-concept:C2699007 | lld:lifeskim |
| pubmed-article:17083268 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17083268 | pubmed:dateCreated | 2006-11-6 | lld:pubmed |
| pubmed-article:17083268 | pubmed:abstractText | The VIOS (Vascular Improvement with Olmesartan medoxomil Study) study is a randomized, parallel study to determine the relative effects of suppressing the renin-angiotensin system (RAS) with the angiotensin receptor antagonist olmesartan medoxomil versus suppressing sympathetic drive with the beta-adrenoceptor antagonist atenolol on remodeling of the subcutaneous small resistance vessel. Remodeling of small resistance vessels may be the earliest pathologic finding associated with hypertension. It may predate the onset of clinically apparent hypertension. | lld:pubmed |
| pubmed-article:17083268 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17083268 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17083268 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17083268 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17083268 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17083268 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17083268 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17083268 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17083268 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17083268 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17083268 | pubmed:issn | 1175-3277 | lld:pubmed |
| pubmed-article:17083268 | pubmed:author | pubmed-author:FerrarioCarlo... | lld:pubmed |
| pubmed-article:17083268 | pubmed:author | pubmed-author:BrosnihanK... | lld:pubmed |
| pubmed-article:17083268 | pubmed:author | pubmed-author:YokoyamaHiros... | lld:pubmed |
| pubmed-article:17083268 | pubmed:author | pubmed-author:SchiffrinErne... | lld:pubmed |
| pubmed-article:17083268 | pubmed:author | pubmed-author:AverillDavid... | lld:pubmed |
| pubmed-article:17083268 | pubmed:author | pubmed-author:SmithRonald... | lld:pubmed |
| pubmed-article:17083268 | pubmed:author | pubmed-author:CookeLoriL | lld:pubmed |
| pubmed-article:17083268 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17083268 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:17083268 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17083268 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17083268 | pubmed:pagination | 335-42 | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:meshHeading | pubmed-meshheading:17083268... | lld:pubmed |
| pubmed-article:17083268 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:17083268 | pubmed:articleTitle | The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. | lld:pubmed |
| pubmed-article:17083268 | pubmed:affiliation | Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA. rosmith@wfubmc.edu | lld:pubmed |
| pubmed-article:17083268 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17083268 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:17083268 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17083268 | lld:pubmed |
